Cargando…
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, which accounts for approximately 3% of cases of breast malignancies. Diagnosis relies largely on its clinical presentation, and despite a characteristic phenotype, underlying molecular mechanisms are poorly understood....
Autores principales: | Costa, Ricardo, Santa-Maria, Cesar A, Rossi, Giovanna, Carneiro, Benedito A, Chae, Young Kwang, Gradishar, William J, Giles, Francis J, Cristofanilli, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355355/ https://www.ncbi.nlm.nih.gov/pubmed/27926493 http://dx.doi.org/10.18632/oncotarget.13778 |
Ejemplares similares
-
Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities
por: Costa, Ricardo, et al.
Publicado: (2017) -
The challenge of developmental therapeutics for adrenocortical carcinoma
por: Costa, Ricardo, et al.
Publicado: (2016) -
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
por: Chae, Young Kwang, et al.
Publicado: (2016) -
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
por: Chuzi, Sarah, et al.
Publicado: (2017) -
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
por: Chae, Young Kwang, et al.
Publicado: (2016)